ClinicalTrials.gov record
Terminated Phase 1Phase 2 Interventional Results available

Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma

ClinicalTrials.gov ID: NCT02266147

Public ClinicalTrials.gov record NCT02266147. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 15, 2026, 6:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, Non-randomized, Open-label, Multicenter, Dose Escalation and Expansion Study of Intratumoral Injections of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma

Study identification

NCT ID
NCT02266147
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Dynavax Technologies Corporation
Industry
Enrollment
29 participants

Conditions and interventions

Interventions

  • Radiation therapy Radiation
  • SD-101 Drug

Radiation · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2014
Primary completion
Mar 31, 2017
Completion
Mar 31, 2017
Last update posted
Sep 3, 2020

2014 – 2017

United States locations

U.S. sites
5
U.S. states
5
U.S. cities
5
Facility City State ZIP Site status
Stanford University School of Medicine Stanford California 94305-5151
Northwestern University Chicago Illinois 60611
University of Iowa Hospitals and Clinics Iowa City Iowa 52242
Washington University School of Medicine St Louis Missouri 63110
University of Rochester Medical Center Rochester New York 14642

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02266147, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 3, 2020 · Synced May 15, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02266147 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →